Bevacizumab
Summary
Risk. The use of amino acids, proteins and peptides is not considered to have any environmental impact.
This summary information comes from assessment report and Fass.
Detailed information
Assessment report
Assessment report for Zirabev (bevacizumab) 13 December 2018EMA/97237/2019.
Bevacizumab is a protein, which is expected to biodegrade in the environment and not be a significant risk to the environment. Thus, according to the “Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use” (EMEA/CHMP/SWP/4447/00), bevacizumab is exempt from preparation of an Environmental Risk Assessment as the product and excipients do not pose a significant risk to the environment.
Fass environmental information
Fass environmental information for Avastin (bevacizumab) from Roche (downloaded 2019-07-10).
The use of amino acids, proteins and peptides is not considered to have any environmental impact.
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00) vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
Author: Health and Medical Care Administration, Region Stockholm